Mohawk Industries
MHK
$128.70
+9.03%
Mohawk Industries is the world's largest flooring manufacturer, producing carpet, rugs, ceramic and porcelain tile, laminate, wood, luxury vinyl tile, and stone products for residential and commercial channels across three reporting segments: Global Ceramic, Flooring North America, and Flooring Rest of the World. The company occupies a scale-driven, vertically integrated position in a highly fragmented and cyclical industry, competing on manufacturing footprint, distribution breadth, and brand portfolio rather than on technology differentiation. The current investor debate centers on whether Mohawk is in the early innings of a housing-led earnings recovery: Q2 2026 revenue grew 6.8% year over year to $2.99 billion and gross margin expanded to 26.6% from 25.5% a year earlier, fueling a sharp August rally, but the stock has since given back a meaningful portion of those gains as investors question the durability of the demand recovery and the pace of margin normalization. With no dividend and a depressed trailing earnings base, the narrative is fundamentally a margin-recovery and operating-leverage story tied to U.S. remodeling activity and European ceramic demand.…
MHK
Mohawk Industries
$128.70
MHK 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Mohawk Industries's 12-month outlook, with a consensus price target around $136.47 and implied upside of +6.0% versus the current price.
Average Target
$136.47
0 analysts
Implied Upside
+6.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$112 - $188
Analyst target range
Coverage is solid with 15 analysts, and the consensus recommendation is "buy" with a mean rating of 2.44 on a scale where lower is more bullish, indicating a moderately constructive but not unanimous stance. The average target price of $136.47 implies roughly 13.5% upside from the current $120.29, a respectable but not aggressive signal that reflects the stock's recent pullback from its August highs. Consensus 2027 EPS estimates of $15.73 (range $15.26-$16.16) and revenue of $12.06 billion underpin the forward PE of 12.1x, suggesting analysts expect a meaningful earnings recovery even as the stock trades below their average target.
The target range is wide, from a low of $112 (about 6.9% downside) to a high of $188 (about 56% upside), a spread of roughly 68% of the current price that signals genuine disagreement about the pace of the housing and remodeling recovery. The high target likely assumes multiple expansion toward mid-cycle margins and a housing-led volume rebound, while the low target prices in a prolonged demand slump and margin compression. Institutional ratings show a stable-to-cautious tilt: Truist and JP Morgan maintain Buy/Overweight, but RBC, Wells Fargo, Barclays, Baird, and Evercore ISI all sit at Neutral/In Line/Equal Weight, and there have been no recent upgrades, indicating the Street is waiting for confirmation of the margin recovery before turning more constructive.
Bulls vs Bears: MHK Investment Factors
The bear case currently has slightly stronger near-term evidence: MHK has underperformed SPY by 20.81 percentage points over the past year and 7.02 points over the past month, and the stock has failed twice near resistance while trailing margins (3.43% net) remain far below mid-cycle. However, the bull case rests on harder fundamental data — sequential revenue acceleration to $2.991 billion, gross margin expansion to 26.58%, and a 12.09x forward PE that already discounts substantial skepticism. The single most important tension is whether the Q2 margin recovery is durable: if gross margins hold above 26% and revenue growth sustains near 7%, the forward earnings estimate of $15.73 becomes credible and the stock re-rates toward the $136.47 consensus target; if margins roll back toward the 23.5% Q1 level, the low multiple becomes a value trap rather than a cushion. Analyst positioning (buy consensus but five Neutral ratings and no upgrades) confirms the Street is waiting for confirmation rather than leading the recovery.
Bullish
- Forward PE of 12.1x prices in recovery: MHK trades at 18.34x trailing but only 12.09x forward earnings on consensus 2027 EPS of $15.73, a 34% multiple compression that implies the market expects earnings to roughly double as margins normalize. For a company with $811.5 million in trailing free cash flow and 0.29x debt-to-equity, that forward multiple is undemanding if the recovery materializes.
- Margin expansion shows real operating leverage: Gross margin rose to 26.58% in Q2 2026 from 23.52% in Q1 and 24.57% in Q4 2025, while operating margin jumped to 8.48% from 4.10% sequentially. Net income climbed from $42.0 million in Q4 2025 to $117.1 million in Q1 to $196.1 million in Q2, demonstrating that incremental volume drops through to the bottom line at a high rate.
- Revenue re-accelerating off cyclical trough: Q2 2026 revenue of $2.991 billion grew 6.76% year over year, following Q1's 8.0% growth, with sequential revenue climbing from $2.700 billion to $2.729 billion to $2.991 billion. This is the strongest top-line momentum in several quarters, led by the $1.192 billion Global Ceramic franchise.
- Deep-value balance sheet and book multiple: At 0.81x price-to-book and 0.63x price-to-sales, MHK trades below the value of its asset base despite $849.6 million in cash, a 2.19 current ratio, and 52.9x interest coverage. The 7.36x EV/EBITDA is far below the roughly 21x-34x range seen in 2025-2026 quarterly snapshots.
Bearish
- Severe relative underperformance versus market: MHK is down 5.28% over the past year against a 15.53% gain for SPY, a relative-strength gap of -20.81 percentage points, and down 5.80% over the past month versus SPY's +1.22% (a -7.02 point gap). The stock has failed twice near highs, at $140.10 in August and $121.33 in June, signaling persistent seller pressure.
- Trailing profitability still deeply depressed: Trailing net margin is just 3.43% and operating margin 4.73%, with ROE of 4.42% and ROA of 3.70% — all well below mid-cycle norms. The 23.87% gross margin in the valuation dataset versus 26.58% in the latest quarter shows how much of the recovery is still unproven.
- Wide analyst target dispersion signals uncertainty: Targets range from $112 (6.9% downside) to $188 (56% upside), a spread of roughly 68% of the current price, reflecting genuine disagreement on the housing recovery pace. RBC, Wells Fargo, Barclays, Baird, and Evercore ISI all sit at Neutral/In Line/Equal Weight with no recent upgrades.
- Cyclical exposure with elevated volatility: Beta of 1.168 makes MHK roughly 17% more volatile than the market, and the -32.5% max drawdown over the period underscores cyclical downside. A 4.99 short ratio implies a moderately crowded short base that could amplify declines if the recovery thesis falters.
MHK Technical Analysis
MHK is in a choppy, range-bound recovery rather than a clean uptrend: the stock is down 5.28% over the past year versus a 15.53% gain for SPY, a relative-strength gap of -20.81 percentage points, yet it is up 9.84% year to date and 10.53% over six months. At $120.29, the shares sit at roughly 58% of the 52-week range of $92.99 to $140.30, having failed twice near the highs (the August peak of $140.10 and the June high of $121.33 area) while holding well above the low. That positioning implies neither momentum-driven overextension nor a falling knife, but a stock consolidating in the middle of its range awaiting a fundamental catalyst.
Short-term momentum has clearly decelerated: the stock is down 5.80% over the past month against a 1.22% gain for SPY, a -7.02 percentage point relative-strength gap, and the most recent session fell 2.91% from $123.90 to $120.29 on volume of about 1.77 million shares. This one-month weakness conflicts with the positive 3-month (+7.88%) and 6-month (+10.53%) trends, a divergence that looks more like mean reversion after the August spike than a trend reversal, given the higher lows since the September 21 dip to $117.27. The pattern of a sharp August breakout followed by a September-October fade suggests the market is digesting gains rather than distributing, though the failure to hold above $130 is a caution flag.
Key technical levels are well defined: resistance sits at the 52-week high of $140.30, with intermediate resistance around $130-$136 where the August rally stalled, while support rests at the September swing low near $117 and, more importantly, the 52-week low of $92.99. A breakout above $140.30 would confirm a new leg higher and likely force short covering, whereas a breakdown below $117 would put the $93 floor in play and signal the recovery thesis is failing. With a beta of 1.168, MHK is roughly 17% more volatile than the market, and a max drawdown of -32.5% over the period underscores that position sizing should account for meaningful cyclical downside; the 4.99 short ratio also implies a moderately crowded short base that could amplify moves in either direction.
Beta
1.17
1.17x market volatility
Max Drawdown
-31.1%
Largest decline past year
52-Week Range
$93-$140
Price range past year
Annual Return
+0.3%
Cumulative gain past year
| Period | MHK Return | S&P 500 |
|---|---|---|
| 1m | +6.2% | -1.2% |
| 3m | +13.6% | +3.4% |
| 6m | +19.5% | +7.0% |
| 1y | +0.3% | +14.4% |
| ytd | +17.5% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MHK Fundamental Analysis
Revenue is re-accelerating off a cyclical trough: Q2 2026 revenue of $2.991 billion rose 6.76% year over year from $2.802 billion, following Q1 2026 revenue of $2.729 billion (up 8.0% from $2.526 billion in Q1 2025) and Q4 2025 revenue of $2.700 billion (up 2.4% from $2.637 billion). The sequential climb from $2.700 billion to $2.729 billion to $2.991 billion marks the strongest top-line momentum in several quarters, and segment data shows Global Ceramic at $1.192 billion, Carpet and Resilient at $990 million, and Laminate and Wood at $483 million, with the ceramic franchise the largest contributor. The trajectory implies the investment case is shifting from defense to recovery, though the 6.8% growth rate remains modest for a company with 40,500 employees and heavy fixed-cost leverage.
Profitability is improving but from a low base: Q2 2026 net income of $196.1 million produced a 6.56% net margin and EPS of $3.23, up sharply from Q1 2026's $117.1 million (4.29% margin, $1.91 EPS) and Q4 2025's $42.0 million (1.56% margin, $0.68 EPS). Gross margin expanded to 26.58% in Q2 from 23.52% in Q1 and 24.57% in Q4 2025, while operating margin reached 8.48% versus 4.10% in Q1, evidence of operating leverage as volume returns. Still, the trailing net margin of 3.43% and operating margin of 4.73% remain well below the company's mid-cycle norms, and the 23.87% gross margin in the valuation dataset versus 26.58% in the latest quarter highlights how much of the recovery is still ahead.
Balance sheet health is a relative strength: debt-to-equity is just 0.293, the current ratio is 2.19, and interest coverage in the latest quarter was roughly 52.9x on $4.8 million of interest expense against $253.7 million of operating income. Free cash flow is robust at $811.5 million trailing twelve months, with Q2 2026 FCF of $228.2 million on $316.5 million of operating cash flow and $88.3 million of capex, and cash stands at $849.6 million. However, ROE of 4.42% and ROA of 3.70% remain depressed, and the company continues to retire debt and buy back stock ($59.9 million repurchased in Q2), signaling confidence but also that internal cash generation, not external financing, funds the business.
Quarterly Revenue
$3.0B
2026-07
Revenue YoY Growth
+6.8%
YoY Comparison
Gross Margin
26.6%
Latest Quarter
Free Cash Flow
$811500000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MHK Overvalued?
Because net income is positive ($196.1 million in Q2 2026), the PE ratio is the appropriate primary metric: MHK trades at 18.34x trailing earnings but only 12.09x forward earnings, a 34% compression that implies the market expects EPS to roughly double as margins normalize. That gap is the crux of the valuation debate, and the forward multiple of 12.1x on consensus 2027 EPS of about $15.73 (per analyst estimates) is undemanding for a cyclical recovery story if the earnings materialize. The PEG ratio of -0.68 is not meaningful given the depressed trailing earnings base, so forward PE and EV/EBITDA are the more reliable anchors.
Relative to the broader market and its own history, MHK screens cheap: the PS ratio of 0.63, price-to-book of 0.81, and EV/EBITDA of 7.36x are all well below the market average and below the stock's own recent history, where EV/EBITDA ranged from roughly 21x to 34x across 2025-2026 quarterly snapshots. The 0.81x book value is particularly notable for a company with $849.6 million in cash and modest leverage, suggesting the market is pricing in a below-cost-of-capital return on the existing asset base. Peer comparison data for the Furnishings, Fixtures & Appliances industry is not available in the provided dataset, so a precise premium/discount spread cannot be quantified, but the absolute multiples are consistent with a deep-cyclical trough valuation.
Historically, MHK's PE has swung wildly with the earnings cycle, from 9.2x in Q2 2026 to 40.2x in Q4 2025 and negative readings during loss quarters in 2022-2023, while PS has compressed from 4.44x in Q4 2021 to 0.63x today. The current PS of 0.63 is near the bottom of the multi-year band, and the forward PE of 12.1x sits in the lower half of the historical range, implying the market is pricing in recovery but not optimism. If margins normalize toward mid-cycle levels, the stock could re-rate on both earnings growth and multiple expansion; if the housing recovery stalls, the low multiple offers limited downside cushion given the 0.81x book value.
PE
18.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 7x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the fragility of the margin recovery. Trailing net margin of 3.43% and operating margin of 4.73% sit far below mid-cycle norms, and the swing from Q1's 23.52% gross margin to Q2's 26.58% shows how sensitive earnings are to volume — a single soft quarter could erase the operating leverage that drove net income from $42.0 million in Q4 2025 to $196.1 million in Q2 2026. Revenue is concentrated in Global Ceramic at $1.192 billion of the $2.991 billion quarterly total, tying results heavily to European and U.S. tile demand, while the 40,500-employee fixed-cost base means volume declines hit margins disproportionately. Balance sheet risk is low (debt-to-equity 0.293, current ratio 2.19, interest coverage ~52.9x), but ROE of 4.42% and ROA of 3.70% indicate the asset base is underearning, and the absence of a dividend removes any income buffer.
Market and competitive risks are dominated by valuation compression and cyclical sensitivity. At 0.81x book and 0.63x sales, MHK is cheap in absolute terms, but that discount reflects a fragmented, commoditized flooring industry where the company competes on manufacturing footprint and distribution rather than technology differentiation. Beta of 1.168 means a 10% market decline would imply roughly an 11.7% drop, and the -32.5% max drawdown over the period shows how violently the stock moves in downturns. The 4.99 short ratio adds a crowded-short dynamic that can amplify moves in either direction, and with five of fifteen analysts at Neutral and no recent upgrades, sentiment could deteriorate quickly if housing data disappoints.
The worst-case scenario is a stalled U.S. remodeling recovery combined with weakening European ceramic demand, which would reverse the margin gains and push earnings back toward the Q4 2025 run-rate of $0.68 quarterly EPS. In that chain of events, the stock would likely retest the 52-week low of $92.99, representing roughly -22.7% from the current $120.29, and the analyst low target of $112 (-6.9%) would likely be revised lower. A more severe outcome — a full cyclical downturn similar to the -32.5% max drawdown — would imply a price near $81, though the 0.81x book value and $849.6 million cash balance provide some valuation floor below the 52-week low. Realistically, investors should size positions for a -23% to -33% downside scenario if the recovery thesis fails.